MEDFORD, N.Y., Nov. 11, 2004 (PRIMEZONE) -- Chembio Diagnostics, Inc. (OTCBB:CEMI), a leading point-of-care diagnostic company, announced today that its CEO Lawrence Seibert was showcased on CEOCast.com, a wide-reaching online community of investors and investment professionals. This discussion includes information about the company's latest developments, recent milestones and insight into its future direction. This briefing follows Chembio Diagnostics' recent announcement regarding its registration statement on Form SB-2 becoming effective with the Securities and Exchange Commission on November 4, 2004. This interview can be viewed at www.CEOCast.com, free of charge until November 17, 2004.
"We are extremely pleased to introduce Chembio to the investment community," said Lawrence A. Siebert, President of Chembio Diagnostics, Inc. "CEOCast is an excellent platform to assist us in informing the marketplace about our latest developments."
Information about Sure Check HIV and HIV Stat-Pak, the company's proprietary rapid tests for the detection of antibodies to HIV in finger stick whole blood, serum or plasma was discussed. These tests are utilized by numerous developing nations throughout the world as a means of screening for HIV and thereby facilitating further preventative measures. Currently, Chembio Diagnostics, Inc. is conducting clinical trials for the tests in the United States that are expected to be completed before year-end. Chembio's international marketing strategy for these tests, as well as Chembio rapid test projects in the areas of Mad Cow Disease and Dental Bacteria were touched upon.
About Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc. possesses expertise in the development and manufacturing of rapid test products for various infectious diseases including HIV, Tuberculosis and Mad Cow Disease. As part of Chembio's strategy to provide its HIV rapid tests to millions of people worldwide through governmental and non-governmental agencies and through selected distributors and strategic partners, Chembio Diagnostics, Inc. (through its subsidiary Chembio Diagnostic Systems Inc.) has recently participated in numerous evaluations of its HIV rapid tests with leading agencies and companies around the world. Chembio is currently completing clinical trials in the United States for two of its HIV rapid tests, Sure Check and HIV Stat Pak, in support of a planned submission to the FDA for U.S. regulatory approval which is anticipated in 2005. Chembio signed a technology transfer agreement with the Oswaldo Cruz Institute in February 2004 for one of its HIV tests and is a supplier to Prionics AG for a new rapid test for Mad Cow Disease that has been developed and is awaiting regulatory clearance in Europe. Chembio's headquarters are located at 3661 Horseblock Road, Medford, NY 11763. Chembio's telephone number is 631-924-1135. Email can be directed to info@chembio.com. Additional information can be found at http://www.chembio.com.
About CEOCast
CEOCast is the premier source of original and syndicated streaming broadcast interviews of CEOs at public and private news making companies. The format is organized by industry. Its analysts average over 15 years experience covering and evaluating Wall Street's leading companies. CEOCast programming is distributed to millions of online investors at over 700 financial industry sites as well as to more than 20,000 portfolio managers, buy-side analysts and traders at more than 3,300 financial institutions. All content is copyrighted to protect licensing partners.
Forward Looking Statements
This release contains forward-looking statements regarding Chembio's future plans and expected performance that are based on assumptions and expectations that Chembio believes are reasonable. A number of risks, uncertainties and other factors could cause any of the assumptions and expectations to be incorrect and could cause actual results to differ materially from those reflected in the forward-looking statements. Some of these risks, uncertainties and other factors include, but are not limited to, the demand for our products, our ability to obtain our products from our suppliers, our ability to maintain commercially feasible margins given significant competition, and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. Chembio undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. Readers should carefully review the risks described in other documents that Chembio files from time to time with the Securities and Exchange Commission, including its Registration Statement on Form SB-2, a copy of which is located at www.sec.gov.